Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

RECOMMENDATION FROM THE NOMINATION COMMITTEE TO VOTE “NO” TO SAND GROVE’S PROPOSAL

We refer to Sand Grove Capital Management LLP’s (“Sand Grove”) proposal to replace the Chairman of the Nomination Committee before the expiration of his term at the extraordinary general meeting it has requested on 15 January 2021. The Committee does not support this proposal. The Nomination Committee is of the opinion that the company’s largest shareholder, Sand Grove, should as a principle be represented in the Nomination Committee. As a result, the current chairman of the Committee has several times, both before and after Sand Grove’s failed extraordinary general meeting in September,

Flexion Mobile signs Illusion Connect from Superprism Technology

LONDON, 7th of January, 2021 – Flexion Mobile Plc (Nasdaq: FLEXM), the Android games distribution company today announced that it has signed an agreement with Superprism Technology for Illusion Connect. It is a newly launched and successful real-time strategy game. The game was launched in Google Play in October 2020 and according to Sensor Tower it generated more than USD 1 million net revenue in December 2020 in Google Play. Distribution rights have been secured for all Flexion key channels. Flexion currently has a live portfolio of 20 games and 4 games pending launch.

OncoZenge announces issue of European Patent related to BupiZenge[®]

OncoZenge AB (publ), Moberg Pharma’s subsidiary, today announced that the European Patent Office (EPO) has granted patent 3 284 459 which protects BupiZenge[®], currently in development for treatment of pain due to oral mucositis. The patent is expected to be in effect until 2032.The new patent protects sustained-release lozenge containing bupivacaine, for treatment or alleviation of pain in the oral cavity. It is a divisional of the previously granted European patent 2 701 681, that specifically protects the use of lozenges for treatment of pain due to oral mucositis for cancer patients.

OncoZenge announces issue of European Patent related to BupiZenge[®]

OncoZenge AB (publ), Moberg Pharma’s subsidiary, today announced that the European Patent Office (EPO) has granted patent 3 284 459 which protects BupiZenge[®], currently in development for treatment of pain due to oral mucositis. The patent is expected to be in effect until 2032.The new patent protects sustained-release lozenge containing bupivacaine, for treatment or alleviation of pain in the oral cavity. It is a divisional of the previously granted European patent 2 701 681, that specifically protects the use of lozenges for treatment of pain due to oral mucositis for cancer patients.

Qlife CE-marks COVID-19 test

Qlife announces that the company has CE-marked its PCR test for Sars-CoV-2 for professional use on the mobile test platform Egoo.Health and that the commercialization can begin immediately.The current CE-mark applies to the professional use of the test platform Egoo.Health for sale on the European market. The next step is to place the COVID-19 test in strategic locations, where it can offer fast and reliable results with help from healthcare professionals. “With this CE-marking, Qlife has achieved an important regulatory milestone. Our COVID-19-test is one of the first mobile PCR tests

LMC, Subsidiary of Alma Career, Acquires a Czech Start-up to Reinforce IT Recruitment Services

Alma Media Corporation                                         Press release                         7 January,  2021 LMC, SUBSIDIARY OF ALMA CAREER, ACQUIRES A CZECH START-UP TO REINFORCE IT RECRUITMENT SERVICES A leading recruitment service company in the Czech Republic LMC s.r.o, a member of the Alma Media Group and a subsidiary of Alma Career Oy, has acquired a Czech start-up Quantiq s.r.o. The company’s SaaS-based recruitment service Techloop.io is a niche portal designed for IT professionals and businesses. The parties have agreed not to disclose the price of the transaction.

Skanska builds Orlando Health Jewett Orthopedic Institute in Florida, USA, for about USD 64M, about SEK 524M

Skanska has signed a contract with Orlando Health, Inc. to construct the new Orlando Health Jewett Orthopedic Institute in Orlando, Florida, USA. The contract is worth about USD 64M, about SEK 524M, which will be included in the US order bookings for the fourth quarter 2020.The new 371,000-square-foot (about 35,000 sqm) institute will include an eight-story hospital that will house 75 inpatient rooms and 10 operating rooms (ORs). An adjoining 6-story medical office building will include two floors of ambulatory suites which will contain an added 12 ORs. The inpatient and outpatient facility

Peab builds apartments and retail space in Visby

Peab has been commissioned to build 60 apartments and two stores in southern Visby on Gotland. The customer is BRF Ordboken and the contract is worth SEK 106 million.BRF Ordboken is a new residential block that consists of three separate buildings where all the apartments have big balconies and terraces. The buildings will have plastered facades with staircase walls in cement. One of the buildings will have two stores on the ground floor. The residential environment will be modern and the block will have a courtyard with green oases and a pool for association members. “We are very happy

UNION therapeutics A/S receives FDA approval for IND of oral next generation PDE4-inhibitor (orismilast) for investigation in plaque psoriasis

· Orismilast is a next generation oral PDE4-inhibitor with an improved therapeutic window compared to other PDE4-inhibitors · Oral orismilast (UNI50001) has demonstrated proof of concept in patients living with plaque psoriasis and indicated “best-in-class” potential · PDE4-inhibition is a validated pharmacological target published for a broad range of inflammatory indications[1] · The improved therapeutic window of orismilast suggests potential for use in a number of inflammatory conditions, which have so far been limited by the typical narrow therapeutic window of PDE4-inhibitors

Finnair Traffic Performance in December 2020

Finnair Plc                Investor News        7 January 2021 at 9:00 a.m. EET The COVID-19 pandemic impact was clearly visible in the December passenger traffic figures, still strong month for cargo In December, Finnair carried 92,500 passengers, which was 92.0% less than in the corresponding period of 2019 but 8.8% more than in November 2020. The COVID-19 impact, including the exceptionally strict travel restrictions imposed by Finland, still affected all passenger traffic figures. It was visible especially in the North Atlantic figures (no scheduled flights in December). The

Catena Media appoints Göran Blomberg as interim CEO

Catena Media plc (Nasdaq Stockholm: CTM) The Board of Directors of Catena Media PLC announces that Göran Blomberg has been appointed interim CEO of Catena Media. Mr. Blomberg has been a member of the board of Catena Media since 2019 and chairman since 2020. He replaces Per Hellberg who leaves the company today. A search process for a new permanent CEO will now be undertaken.Mr. Blomberg will step down as chairman of the Board during his time as interim CEO. Öystein Engebretsen will serve as acting chairman during Mr. Blomberg’s tenure as CEO. “We are pleased to appoint Göran Blomberg

European Scale-up Action for Risk Capital (ESCALAR) kicks off: First ESCALAR project signed with Swedish equity fund manager eEquity

The first transaction under the joint European Commission and European Investment Fund (EIF) “European Scale-up Action for Risk capital” (ESCALAR) pilot programme, backed by the Investment Plan for Europe, has been signed. The first project concerns eEquity IV fund, which will support scale-ups and high-growth SMEs and small mid-caps in several EU Member States, with a focus on the Nordics.eEquity, a digital growth equity investor in the Nordics, announces the final close of eEquity IV, which will invest growth capital in disruptive European internet businesses. The fund benefits from a SEK

Skanska builds Hartsfield-Jackson Atlanta International Airport Concourse T-North Extension in Georgia, USA, for about USD 56M, about SEK 460M

Skanska has signed an additional contract with Hartsfield-Jackson Atlanta International Airport to construct the Concourse T-North Extension and modernization project in Atlanta, Georgia, USA, in a Skanska-led joint venture along with New South Construction, FS360 and Synergy Construction. Skanska’s share of the contract is worth about USD 56M, about SEK 460M, which will be included in the US order bookings for the fourth quarter 2020.The expansion and modernization at the world’s busiest passenger airport will include the construction of five additional gates at the north end of Concourse

Pexip Announces Annual Recurring Revenue Growth of 73 %

(Oslo, Norway, 7 January 2021) In this trading update, Pexip presents its Annual Recurring Revenue (ARR) for the fourth quarter (Q4) of 2020. In Q4 2020, Pexip increased its ARR with 73% year-on-year to USD 81.9 million.·Pexip’s subscription base measured in ARR reached USD 81.9 million in Q4 2020, up from USD 47.2 million in Q4 2019, representing a year-on-year increase of 73%. · Of the 73% year-on-year growth in ARR, 59 percentage points (pp) are from new customers and 14 pp are from existing customers. Net revenue retention rate, reflecting the percent of retained revenue from

Stay focused on your goals – Staffordshire University is here to help

With the cancellation of GCSE, AS Level and A Level examinations in the wake of the new lockdown, Staffordshire University is urging prospective applicants to stay focused and take advantage of the support available to themStaffordshire University is urging prospective applicants to stay focused on their study goals in the wake of the latest national lockdown and the announcement that GCSE, AS Level and A Level examinations for summer 2021 have been cancelled. The new restrictions, announced by Prime Minister Boris Johnson in response to the rising number of COVID-19 cases across the UK,

Scandion Oncology’s rights issue registered with the Danish Business Authority – BTAs are converted to shares

Scandion Oncology A/S ("Scandion" or the "Company") has carried out a rights issue of approximately SEK 236 million. Today, on 6 January 2021, the share capital increase and updated articles of association have been registered with the Danish Business Authority.The last day of trading in paid subscribed shares (BTAs) is 12 January 2021. BTAs will be converted to shares on 18 January 2021 and the ISIN code for the BTAs will be merged with the permanent ISIN code on 18 January 2021. The newly issued shares are expected to be delivered to the shareholders’ securities accounts on 18 January

Company Announcement No. 2, 2021 - Auction of covered mortgage bonds in Nordea Kredit Realkreditaktieselskab

With the refinancing of Nordea Kredit Realkreditaktieselskab's adjustable rate mortgages (ARMs) as of 1 April 2021 an electronic auction will be held in February 2021. The ARMs will be refinanced in covered mortgage bonds (SDRO). Nordea Danmark will conduct the auction. The Auction                      The auction will be held in the auction market for mortgage bonds at NASDAQ Copenhagen. The Dutch (hidden call) auction principle will be applied, implying that where bids exceed the cut-off price, the full amount will be allocated at the cut-off price. Bids made at the cut-off price

2020 Bulkers Ltd. (2020) – Voyage charter for Bulk Shenzhen

Hamilton, Bermuda, 6 January 2021, 2020 Bulkers is pleased to announce that the Bulk Shenzhen has been fixed on a voyage charter with estimated duration until mid-April 2021. The voyage charter is expected to generate time charter equivalent earnings of approximately US$18,500 per day, net. For further queries, please contact:  Magnus Halvorsen, Chief Executive Officer, 2020 Bulkers Management AS Telephone +47 920 20 111 About 2020 Bulkers Ltd.: 2020 Bulkers has eight Newcastlemax dry bulk vessels in operation. All vessels are fitted with exhaust scrubber systems.

NOTIFICATION OF MANAGERS’ AND CLOSELY RELATED PARTIES’ TRANSACTIONS WITH DAMPSKIBSSELSKABET NORDEN A/S’ SHARES IN CONNECTION WITH SHARE BUY-BACK PROGRAM

ANNOUNCEMENT NO. 4 - 6 JANUARY 2021 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcement no. 90/2020. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information: Martin Badsted, CFO, tel.: +45 3315 0451

Q-Free: Conversion of convertible bonds

Reference is made to the stock exchange notice published 5 January 2021 regarding Rieber & Søn AS' conversion of its portion of Q-Free ASA's NOK 80 million unsecured subordinated convertible bond loan (the "Convertible Bond Loan"), for an aggregate principal amount of NOK 49,500,000. Q-Free ASA has now received conversion notices from the paying and conversion agent for the Convertible Bond Loan for bonds representing an additional amount of NOK 2,500,000. The aggregated received conversion notices representing NOK 52,000,000 of the Convertible Bond Loan will be converted into 14,313,633

Farxiga granted Priority Review in the US for the treatment of patients with chronic kidney disease

6 January 2021 07:00 GMT Farxiga granted Priority Review in the USfor the treatment of patients with chronic kidney disease Farxiga could become the first SGLT2 inhibitor approved to treatpatients with chronic kidney disease, with and without type-2 diabetes AstraZeneca's Farxiga (dapagliflozin) has been granted Priority Review in the US for the treatment of new or worsening chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). The Food and Drug Administration (FDA) grants Priority Review to regulatory submissions for medicines that offer significant

Targovax grants IOVaxis 3 months extension to the exclusive license option for TG mutant RAS vaccines in Greater China and Singapore

· COVID-19 have caused delays to submission and processing of the regulatory application to initiate clinical development in China · Due to the unforeseen delays, Targovax has extended the term of IOvaxis´s license option by 3 months, otherwise the agreement remains unchanged Oslo, Norway 6 January 2021 – Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that it has granted an extension of 3 months to the exclusive option agreement with IOVaxis Therapeutics of Nantong, China, for

Hexagon Composites ASA: Invitation to Capital Markets Day 2021

Hexagon Composites invites shareholders, analysts, media and other stakeholders to our Virtual Capital Markets Day on Monday 11 January 2021, from 13:00 – 16:00 CET. Presentations will be held by Hexagon’s executive management with a focus on the company’s solutions and positioning for further growth. Presentations will be followed by Q&A. To attend our Capital Markets Day, please register here.  Agenda 11 January 2021 - Clean Air Everywhere 13:00 – 13:10 CET

ShaMaran Achieves 40 Million Barrels Atrush Oil Production and January Interest Payment Timely Paid in Full

VANCOUVER, BRITISH COLUMBIA, January 5, 2021 /CNW/ - ShaMaran Petroleum Corp. ("ShaMaran" or the “Company”) (SNM - TSXV, Nasdaq First North Growth Market) is pleased to announce that the January 2021 interest payment due on its 12% senior unsecured bonds due 2023 (ISIN: NO 001082645.6) has been timely made to all Bondholders. In addition, ShaMaran is also pleased to announce that the Atrush field total cumulative crude oil production has exceeded 40 million barrels. The Atrush field is located 85 km northwest of Erbil and is one of the largest new oil developments in the Kurdistan Region

There are no items matching the current filter
There are no more items matching the current filter
Back to top